Here's Why argenx SE (ARGX) Rose in Q3

ClearBridge Investments, an investment management company, released its “ClearBridge Mid Cap Strategy” third-quarter 2025 investor letter. A copy of the letter can be downloaded here. In an environment of shifting monetary policy, stabilizing earnings, and improved sentiment, midcaps experienced growth in the third quarter. The Federal Reserve’s decision to cut rates helped small and mid-cap stocks in the quarter. Value stocks outperformed their growth counterparts with the Russell Midcap Value Index returning 6.2% compared to the Russell Midcap Growth’s 2.8% return. In this environment, the strategy outperformed its Russell Midcap Index during the third quarter. Stock selection in the consumer staples and healthcare sectors drove outperformance of the strategy. In addition, please check the fund’s top five holdings to know its best picks in 2025.

In its third-quarter 2025 investor letter, ClearBridge Mid Cap Strategy highlighted stocks such as Argenx SE (NASDAQ:ARGX). Argenx SE (NASDAQ:ARGX) is a commercial-stage biopharma company. The one-month return of Argenx SE (NASDAQ:ARGX) was 9.11%, and its shares gained 48.48% of their value over the last 52 weeks. On November 12, 2025, Argenx SE (NASDAQ:ARGX) stock closed at $889.89 per share, with a market capitalization of $54.79 billion.

ClearBridge Mid Cap Strategy stated the following regarding Argenx SE (NASDAQ:ARGX) in its third quarter 2025 investor letter:

"Health care was another key driver of outperformance, anchored by strength in biotechnology and the addition of new opportunities in life sciences tools. Argenx SE (NASDAQ:ARGX) delivered robust second-quarter results, supported by continued adoption of its lead therapy for autoimmune disorders and promising progress across its clinical pipeline."

Argenx SE (NASDAQ:ARGX) is not on our list of 30 Most Popular Stocks Among Hedge Funds. According to our database, 53 hedge fund portfolios held Argenx SE (NASDAQ:ARGX) at the end of the second quarter, compared to 54 in the previous quarter. While we acknowledge the potential of Argenx SE (NASDAQ:ARGX) as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

In another article, we covered Argenx SE (NASDAQ:ARGX) and shared Baron Health Care Fund's views on the company. In addition, please check out our hedge fund investor letters Q3 2025 page for more investor letters from hedge funds and other leading investors.

READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money.

Disclosure: None. This article is originally published at Insider Monkey.